1.61  0.02 (1.26%)		04-24 16:00
Open: 1.572 High: 1.64 Volume: 30,748		Pre. Close: 1.59 Low: 1.572 Market Cap: 62(M)

Short term
Mid term
Targets	6-month :	2.02	1-year :	2.36
Resists	First :	1.73	Second :	2.02
Pivot price	1.58
Supports	First :	1.55	Second :	1.44
MAs	MA(5) :	1.59	MA(20) :	1.59
	MA(100) :	1.88	MA(250) :	2.12
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	55.4	D(3) :	51.2
RSI	RSI(14): 49.2
52-week	High :	3.34	Low :	1.3

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OKYO ] has closed below upper band by 35.7%. Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.64 - 1.65	1.65 - 1.66
Low:	1.55 - 1.56	1.56 - 1.57
Close:	1.59 - 1.61	1.61 - 1.63

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Tue, 07 Apr 2026
OKYO Pharma to hold advisory board meeting at ASCRS annual event - Investing.com

Tue, 07 Apr 2026
OKYO Pharma (OKYO) showcases urcosimod Phase 2 data and plans 150-patient trial - Stock Titan

Tue, 07 Apr 2026
OKYO Pharma to hold advisory board meeting at ASCRS conference - Investing.com

Tue, 07 Apr 2026
Eye pain drug data gets ASCRS spotlight ahead of OKYO's next trial - Stock Titan

Tue, 07 Apr 2026
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026 - Yahoo Finance

Thu, 19 Mar 2026
OKYO Pharma founder-linked firm buys 10,119 more shares - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	52 (M)
Shares Float	23 (M)
Held by Insiders	30.4 (%)
Held by Institutions	9 (%)
Shares Short	206 (K)
Shares Short P.Month	435 (K)

EPS	-0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.1
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-104.7 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.12
Sales Per Share	0
EBITDA (p.s.)	-0.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-14.64
PEG Ratio	0
Price to Book value	-17.89
Price to Sales	0
Price to Cash Flow	-27.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.